Laurel Wealth Advisors (North Carolina)’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-300	Closed	-$1K	–	629
2022 Q2	$1K	Hold	300	–	–	﹤0.01%	623
2022 Q1	$1K	Hold	300	–	–	﹤0.01%	658
2021 Q4	$1K	Hold	300	–	–	﹤0.01%	658
2021 Q3	$2K	Hold	300	–	–	﹤0.01%	622
2021 Q2	$3K	Buy	+300	New	+$2.39K	﹤0.01%	652
2021 Q1	–	Sell	-861	Closed	-$6K	–	681
2020 Q4	$6K	Buy	+861	New	+$6.92K	﹤0.01%	466

Other funds holding SRNE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s SRNE Position: Q3 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Sorrento Therapeutics, Inc. (SRNE) in Q3 2022, closing a stake of 300 shares — an estimated $1K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in SRNE in Q4 2020 and held it in 6 quarters. The position peaked at $6K in Q4 2020. 233 funds tracked by Wall St. Rank hold SRNE as of Q3 2022.

Laurel Wealth Advisors (North Carolina) reported no remaining Sorrento Therapeutics, Inc. position as of Q3 2022 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 300 Sorrento Therapeutics, Inc. shares in Q3 2022, an estimated $1K.
Laurel Wealth Advisors (North Carolina) first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 6 quarters.
Laurel Wealth Advisors (North Carolina)'s Sorrento Therapeutics, Inc. position peaked at $6K in Q4 2020.
233 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q3 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q3 2022, filed 15 Nov 2022.